– Company Plans to Use Previously Announced Positive Zimura Clinical Trial as One of Two Pivotal Trials – – Zimura R&D Symposium for Investors/Analysts to be Held on November 20, 2019 – – Conference Call and Webcast Today, November...
HOUSTON, Nov. 12, 2019 /PRNewswire/ — Soliton, Inc., (SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer...
SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1/2 clinical study of its lead drug candidate...
Across all women and all cycles evaluated, Ovaprene prevented essentially all sperm from entering the cervical canal, a surrogate marker for contraceptive effectiveness. Currently marketed contraceptives with similar results in their PCT clinical studies subsequently...
VANCOUVER, Washington, Nov. 11, 2019 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic...
Email
Text